Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease. - Ray GL; Baidoo KE; Keller LM; Albert PS; Brechbiel MW; Milenic DE (Pharmaceuticals (Basel, Switzerland), 2011)